

ASX Announcement

4th April 2023

Capital Raising

4 April 2023 – Medical technology company Singular Health Group Limited (ASX: SHG, “Singular Health”, or the “Company”) is pleased to announce that it has received binding commitments for a two-tranche placement from private and sophisticated investors to raise A\$1,050,000 (before costs).

The raising will be completed via the issue of 19,090,909 new fully paid ordinary shares (“Shares”) at \$0.055 per share plus free attaching options (“Placement”). The Placement is structured with two tranches (“Tranche 1” and “Tranche 2”).

Tranche 1 will close immediately and raise \$423,500 through the issue of 7,699,997 Shares at \$0.055 per share utilising the Company’s existing ASX Listing Rule 7.1 placement capacity. Tranche 1 participants will, subject to shareholder approval, receive one free-attaching option (exercise price of \$0.10 and three-year expiry from date of issue) for every two Tranche 1 placement shares subscribed for.

Tranche 2 is subject to shareholder approval and will raise \$626,500 through the issue of 11,390,912 Shares at \$0.055 per Share with one free-attaching option (exercise price of \$0.10 and three-year expiry from date of issue), for every one Tranche 2 placement share subscribed for.

The Placement was supported by Company Director Denning Chong who contributed \$100,000 to the Placement, as part of Tranche 2, subject to shareholder approval.

The funds will be utilised to complete the commissioning of additional post-processing equipment at the Singular 3DP facility to unlock the orthotic and prosthetic market for custom-made medical devices, development of enterprise-grade solutions for the Company’s 3Dicom MD[®] software required to close currently outstanding and well-progressed enterprise opportunities, and for general working capital.

180 Markets Pty Ltd (“180 Markets”) acted as Lead Manager to the Placement. Subject to shareholder approval, 180 Markets or their nominees will be issued 3,500,000 options (exercise price of \$0.10 and three-year expiry from date of issue) and receive a 6% fee on funds raised from investors they introduced to the Company.

The shareholder meeting to approve the issue of Tranche 2 shares, participation of a Mr Chong (Director) in Tranche 2, the issue of options for both tranches, and the issue of options to 180 Markets is anticipated to be held in approximately 6 weeks’ time. Further details of the meeting and a full notice of meeting will be released shortly.

Singular Health’s Chief Executive Officer and Managing Director, Thomas Hanly, said:

“This capital raising provides a strong foundation for the Company to build on recent achievements including FDA clearance and ISO13485 certification, provide additional runway to fully commission the Singular 3DP facility and to progress a number of commercial opportunities present in the United States market.”

“The Company welcomes its new investors, and thanks existing shareholders for their ongoing support.”

This announcement is authorised for release by the Board of Directors of the Company.

Ends

For further information contact

Investors	Corporate
James Hill +61 413 825 646 jhill@singular.health	Steven Wood Company Secretary + 61 8 9322 7600

About Singular Health:

Singular Health Group Limited (ASX: SHG) is a medical technology company utilising advanced technologies to develop patient-specific solutions.

Singular Health’s 3Dicom software solutions empower patients and practitioners to better visualise, communicate, and understand medical imaging data. 3Dicom MD® is cleared for diagnostic use in the United States

Singular 3DP, a wholly owned subsidiary of Singular Health, uses advanced 3D printing and post-processing to manufacture TGA-approved patient-specific medical devices.

To learn more, please visit: www.singular.health